Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

202129 citationsJournal Articlebronze Open Access

Authors

Michael L. Cheng · Harvard University

Christie J. Lau · Dana-Farber Cancer Institute

Marina S.D. Milan · Harvard University

Julianna Supplee · Dana-Farber Cancer Institute

Jonathan W. Riess · UC Davis Comprehensive Cancer Center

Penelope A. Bradbury · University Health Network

Pasi A. Jänne

Abstract

Plasma ctDNA response is an early phenomenon, with the majority of change detectable within the first cycle of therapy. These kinetics may offer an opportunity for early insight into treatment effect before standard imaging timepoints.

Topics & Keywords

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JCO Precision Oncology

Volume 5, Issue 5, pp. 393-402

DOI: 10.1200/po.20.00419

Field-Weighted Citation Impact: 1.57